Novocure limited NVCR.US Overview
NVCR AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
NVCR Current Performance
-0.95%
Novocure limited
0.98%
Avg of Sector
0.83%
S&P500
NVCR Key Information
NVCR Financial Forecast
Unit : USD
NVCR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.31 | 13.9% | -34% | 154.99M | 11.9% | 0.7% | -40.9% |
| 2024Q3 | -0.61 | -35.6% | 79.4% | 161.27M | 20.5% | 9.3% | -19.7% |
| 2024Q2 | -0.28 | 39.1% | -17.6% | 155.1M | 21.8% | 1.3% | -22.2% |
| 2024Q1 | -0.31 | 42.6% | -22.5% | 150.36M | 19.3% | 4.5% | -28% |
| 2023Q4 | -0.36 | 28% | -16.3% | 138.5M | 13.4% | 2% | -35.2% |
NVCR Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.